From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
animal models
iPS cells
neurodegeneration
pathophysiology
α-synuclein
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
12
10
2020
received:
19
08
2020
accepted:
27
10
2020
pubmed:
18
11
2020
medline:
20
5
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Parkinson's disease (PD) is primarily known as a movement disorder because of typical clinical manifestations associated with the loss of dopaminergic neurons in the substantia nigra. However, it is now widely recognized that PD is a much more complex condition, with multiple and severe nonmotor features implicating additional brain areas and organs in the disease process. Pathologically, typical forms of PD are characterized by the accumulation of α-synuclein-rich protein inclusions known as Lewy bodies and Lewy neurites, although other types of protein inclusions are also often present in the brain. Familial forms of PD have provided a wealth of information about molecular pathways leading to neurodegeneration, but only to add to the complexity of the problem and uncover new knowledge gaps. Therefore, modeling PD in the laboratory has become increasingly challenging. Here, we discuss knowledge gaps and challenges in the use of laboratory models for the study of a disease that is clinically heterogeneous and multifactorial. We propose that the combined use of patient-derived cells and animal models, along with current technological tools, will not only expand our molecular and pathophysiological understanding of PD, but also assist in the identification of therapeutic strategies targeting relevant pathogenic pathways. © 2020 International Parkinson and Movement Disorder Society.
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
832-841Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Schneider SA, Obeso JA. Clinical and pathological features of Parkinson's disease. Curr Top Behav Neurosci 2015;22:205-220.
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18(2):101-113.
den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960;23:283-290.
Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988;76(3):217-221.
Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov Disord 2014;29(4):454-462.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-2301.
Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136(Pt 8):2419-2431.
Fieblinger T, Cenci MA. Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. Mov Disord 2015;30(4):484-493.
Solis O, Limon DI, Flores-Hernandez J, Flores G. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse 2007;61(6):450-458.
Petersson P, Kuhn AA, Neumann WJ, Fuentes R. Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease. Prog Brain Res 2020;252:525-557.
Charron G, Doudnikoff E, Canron MH, et al. Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology? Front Aging Neurosci 2014;6:258.
Kuter KZ, Cenci MA, Carta AR. The role of glia in Parkinson's disease: emerging concepts and therapeutic applications. Prog Brain Res 2020;252:131-168.
Cenci MA. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 2014;5:242.
Ahmed RM, Ke YD, Vucic S, et al. Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 2018;14(5):259-271.
McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012;46(3):597-606.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-840.
McLean PJ, Kawamata H, Hyman BT. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001;104(3):901-912.
Lazaro DF, Rodrigues EF, Langohr R, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet 2014;10(11):e1004741.
Lindersson E, Lundvig D, Petersen C, et al. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 2005;280(7):5703-5715.
Mahul-Mellier AL, Burtscher J, Maharjan N, et al. The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 2020;117(9):4971-4982.
Bezard E. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. Lancet Neurol 2003;2(7):393.
Barker RA, Bjorklund A. Animal models of Parkinson's disease: are they useful or not? J Parkinsons Dis 2020;10(4):1335-1342.
Sittig LJ, Carbonetto P, Engel KA, Krauss KS, Barrios-Camacho CM, Palmer AA. Genetic background limits generalizability of genotype-phenotype relationships. Neuron 2016;91(6):1253-1259.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-676.
Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007;2(12):3081-3089.
Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003;302(5651):1772-1775.
Schondorf DC, Aureli M, McAllister FE, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014;5:4028.
Reinhardt P, Schmid B, Burbulla LF, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013;12(3):354-367.
Laperle AH, Sances S, Yucer N, et al. iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates. Nat Med 2020;26(2):289-299.
Sandor C, Robertson P, Lang C, et al. Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease. Hum Mol Genet 2017;26(3):552-566.
Hendriks WT, Warren CR, Cowan CA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 2016;18(1):53-65.
Liu SP, Fu RH, Huang SJ, et al. Stem cell applications in regenerative medicine for neurological disorders. Cell Transplant 2013;22(4):631-637.
Soldner F, Laganiere J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011;146(2):318-331.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18(12):1091-1102.
Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 2004;101(34):12543-12548.
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27(3):275-280.
Ferreri AJ, Illerhaus G, Zucca E, Cavalli F. International extranodal lymphoma study G. Flows and flaws in primary central nervous system lymphoma. Nat Rev Clin Oncol 2010;7(8):1-2. https://doi.org/10.1038/nrclinonc.2010.1039-c1031 author reply doi:1010:1038/nrclinonc 2010 1039-c1032.
Nolbrant S, Heuer A, Parmar M, Kirkeby A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat Protoc 2017;12(9):1962-1979.
Konagaya S, Ando T, Yamauchi T, Suemori H, Iwata H. Long-term maintenance of human induced pluripotent stem cells by automated cell culture system. Sci Rep 2015;5:16647.
Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013;501(7467):373-379.
Lancaster MA, Corsini NS, Wolfinger S, et al. Guided self-organization and cortical plate formation in human brain organoids. Nat Biotechnol 2017;35(7):659-666.
Kanton S, Boyle MJ, He Z, et al. Organoid single-cell genomic atlas uncovers human-specific features of brain development. Nature 2019;574(7778):418-422.
Pasca AM, Sloan SA, Clarke LE, et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods 2015;12(7):671-678.
Camp JG, Badsha F, Florio M, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci U S A 2015;112(51):15672-15677.
Kadoshima T, Sakaguchi H, Nakano T, et al. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc Natl Acad Sci U S A 2013;110(50):20284-20289.
Jo J, Xiao Y, Sun AX, et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and Neuromelanin-producing neurons. Cell Stem Cell 2016;19(2):248-257.
Qian X, Nguyen HN, Song MM, et al. Brain-region-specific organoids using mini-bioreactors for Modeling ZIKV exposure. Cell 2016;165(5):1238-1254.
Birey F, Andersen J, Makinson CD, et al. Assembly of functionally integrated human forebrain spheroids. Nature 2017;545(7652):54-59.
Sakaguchi H, Kadoshima T, Soen M, et al. Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. Nat Commun 2015;6:8896.
Monzel AS, Smits LM, Hemmer K, et al. Derivation of human midbrain-specific organoids from Neuroepithelial stem cells. Stem Cell Rep 2017;8(5):1144-1154.
Muguruma K, Nishiyama A, Kawakami H, Hashimoto K, Sasai Y. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep 2015;10(4):537-550.
Suga H, Kadoshima T, Minaguchi M, et al. Self-formation of functional adenohypophysis in three-dimensional culture. Nature 2011;480(7375):57-62.
Eiraku M, Watanabe K, Matsuo-Takasaki M, et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008;3(5):519-532.
Quadrato G, Nguyen T, Macosko EZ, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature 2017;545(7652):48-53.
Sloan SA, Darmanis S, Huber N, et al. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron 2017;95(4):779-790. e776.
Javaherian A, Kriegstein A. A stem cell niche for intermediate progenitor cells of the embryonic cortex. Cereb Cortex 2009;19(Suppl 1):i70-i77.
Stubbs D, DeProto J, Nie K, et al. Neurovascular congruence during cerebral cortical development. Cereb Cortex 2009;19(Suppl 1):i32-i41.
Cunningham CL, Martinez-Cerdeno V, Noctor SC. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J Neurosci 2013;33(10):4216-4233.
Abud EM, Ramirez RN, Martinez ES, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron 2017;94(2):278-293. e279.
Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. Neuron 2018;98(6):1141-1154. e1147.
Cenci MA, Bjorklund A. Animal models for preclinical Parkinson's research: an update and critical appraisal. Prog Brain Res 2020;252:27-59.
Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002;3(7):574-579.
Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 2011;42(3):327-340.
Wolfarth S, Konieczny J, Smialowska M, Schulze G, Ossowska K. Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements. Neuroscience 1996;74(4):985-996.
Cenci MA, Francardo V, O'sullivan SS, Lindgren HS. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: how far have we reached? Neurobiol Dis 2015;82:561-573.
Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014;19(3):358-367.
Lindgren HS, Klein A, Dunnett SB. Nigral 6-hydroxydopamine lesion impairs performance in a lateralised choice reaction time task: impact of training and task parameters. Behav Brain Res 2014;266:207-215.
Rossi M, Farcy N, Starkstein SE, Merello M. Nosology and phenomenology of psychosis in movement disorders. Mov disord 2020;7(2):140-153.
Fifel K, Piggins H, Deboer T. Modeling sleep alterations in Parkinson's disease: how close are we to valid translational animal models? Sleep Med Rev 2016;25:95-111.
Metzger JM, Emborg ME. Autonomic dysfunction in Parkinson disease and animal models. Clin Auton Res 2019;29(4):397-414.
Roelfsema PR, Treue S. Basic neuroscience research with nonhuman primates: a small but indispensable component of biomedical research. Neuron 2014;82(6):1200-1204.
Mantini D, Corbetta M, Romani GL, Orban GA, Vanduffel W. Evolutionarily novel functional networks in the human brain? J Neurosci 2013;33(8):3259-3275.
Vila M, Laguna A, Carballo-Carbajal I. Intracellular crowding by age-dependent neuromelanin accumulation disrupts neuronal proteostasis and triggers Parkinson disease pathology. Autophagy 2019;15(11):2028-2030.
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-980.
Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984;292(2):390-394.
Doudet D, Gross C, Lebrun-Grandie P, Bioulac B. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. Brain Res 1985;335(1):194-199.
Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 1985;24(6):587-591.
Porras G, Li Q, Bezard E. Modeling Parkinson's disease in primates: the MPTP model. Cold Spring Harb Perspect Med 2012;2(3):a009308.
Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord 2011;26(6):993-1002.
Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015;132:96-168.
Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 2003;100(5):2884-2889.
Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002;22(7):2780-2791.
Eslamboli A, Romero-Ramos M, Burger C, et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007;130(Pt 3):799-815.
Yang W, Wang G, Wang CE, et al. Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain. J Neurosci 2015;35(21):8345-8358.
Bourdenx M, Dovero S, Engeln M, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun 2015;3:46.
Koprich JB, Johnston TH, Reyes G, Omana V, Brotchie JM. Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson's disease: optimization of AAV1/2 delivery parameters to drive sustained expression of alpha synuclein and dopaminergic degeneration in macaque. PLoS One 2016;11(11):e0167235.
Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28(3):271-274.
Dehay B, Dalkara D, Dovero S, Li Q, Bezard E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Sci Rep 2012;2:253.
Chansel-Debordeaux L, Bourdenx M, Dovero S, et al. In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease. Gene Ther 2017;24(12):801-809.
Garrett DJ, Larson JE, Dunn D, Marrero L, Cohen JC. In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates. BMC Biotechnol 2003;3:16.
Chan AW, Chong KY, Martinovich C, Simerly C, Schatten G. Transgenic monkeys produced by retroviral gene transfer into mature oocytes. Science 2001;291(5502):309-312.
Yang SH, Cheng PH, Banta H, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008;453(7197):921-924.
Tomioka I, Ishibashi H, Minakawa EN, et al. Transgenic monkey model of the Polyglutamine diseases recapitulating progressive neurological symptoms. eNeuro 2017;4(2):1-16.
Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21(17):6853-6861.